SEARCHABLE FDA/EMA DRUG APPROVAL DOCUMENTS

Searchable FDA/EMA Drug Approval documents and extracted comparative data provides essential information for more informed drug development decisions on critical drug safety, risk assessments and mitigation and study designs.
Introduction
PharmaPendium is a decision support solution designed to help improve pharmaceutical development by providing unique comparative pre-clinical, clinical and post-release drug information in a single longitudinal database. In addition, PharmaPendium has fully searchable FDA/EMA drug approval documents that helps you find relevant information in minutes. Part of the portfolio of Elsevier R&D Solutions for Pharma & Life Sciences, it answers critical drug development questions.

- Can I find safety, efficacy and DMPK data to support my analysis of in vitro and in vivo test results?
- Can I compare my drug to approved drugs to help optimize my drug safety analyses and trial design?
- How can I assess PK parameters and potential drug-drug interaction risks for my drug candidate?
- What support can I get for making my case to the regulatory authorities?

FEATURES
UNIQUE CONTENT HELPS YOU GET PROMISING DRUG CANDIDATES TO MARKET FASTER

PharmaPendium provides extracted pre-clinical and clinical safety, pharmacokinetic and metabolizing enzyme and transporter data that you cannot find anywhere else. PharmaPendium gives you access to original FDA/EMA drug approval documents and a whole range of medical and drug development journals along with references from Meyler's Side Effects of Drugs and Mosby's Drug Consult, allowing you to make better drug candidate assessments.
KEY BENEFITS

WHAT DOES THIS MEAN FOR YOU?

• Better risk assessment of your drug candidate’s toxicity
• Detailed assessments of your drug candidate’s PK parameters and properties
• Better assessment of previous pre-clinical experimental design including species selection
• Rapid evaluation of potential drug-drug interaction risks
• Increased chances of successful submissions to regulatory authorities
Further Information
Please visit www.elsevier.com/online-tools/pharmacendium

ASIA AND AUSTRALIA
Tel: +65 6349 0222
Email: sginfo@elsevier.com

JAPAN
Tel: +81 3 5561 5034
Email: jpinfo@elsevier.com

KOREA AND TAIWAN
Tel: +82 2 6714 3000
Email: krinfo.corp@elsevier.com

EUROPE, MIDDLE EAST AND AFRICA
Tel: +31 20 485 3767
Email: nlinfo@elsevier.com

NORTH AMERICA, CENTRAL AMERICA AND CANADA
Tel: +1 888 615 4500
Email: usinfo@elsevier.com

SOUTH AMERICA
Tel: +55 21 3970 9300
Email: brinfo@elsevier.com